How to get rid of man boobs is a question many men ask but few feel comfortable raising with a doctor. Enlarged breast tissue in men — medically termed gynaecomastia — is more common than most people realise and has a range of causes, from hormonal imbalances and medications to excess body fat. Whether the issue is true glandular gynaecomastia or pseudogynaecomastia (fatty tissue), effective options exist, including lifestyle changes, medical treatment, and surgery. This article explains the causes, when to seek help, and the treatment pathways available through the NHS.

What Causes Enlarged Breast Tissue in Men

Enlarged breast tissue in men is caused by an oestrogen-to-androgen imbalance (true gynaecomastia) or excess chest fat (pseudogynaecomastia), with common triggers including puberty, ageing, obesity, medications, and underlying health conditions.

Enlarged breast tissue in men is a medical condition known as gynaecomastia. It is important to distinguish between two distinct presentations: true gynaecomastia, which involves the proliferation of glandular breast tissue, and pseudogynaecomastia, which refers to the accumulation of fatty tissue in the chest area without glandular involvement. Both can cause visible chest enlargement, but they have different underlying causes and treatment pathways.

True gynaecomastia occurs due to an imbalance between oestrogen and androgen (testosterone) activity in the body. Oestrogen stimulates breast tissue growth, while testosterone typically suppresses it. When this hormonal balance is disrupted — whether through increased oestrogen levels, reduced testosterone, or heightened sensitivity of breast tissue to oestrogen — glandular tissue can develop. This hormonal imbalance can arise from a range of causes, including:

• Puberty — a very common and usually temporary cause in adolescent boys

• Ageing — testosterone levels naturally decline with age, particularly after 50

• Obesity — excess body fat increases the conversion of androgens to oestrogens via a process called aromatisation

• Underlying health conditions — such as hypogonadism, Klinefelter syndrome, hyperthyroidism, liver cirrhosis, or chronic kidney disease

• Tumours — rarely, testicular, adrenal, or pituitary tumours (including hCG-secreting tumours) can produce hormones that disrupt this balance; clinical examination of the testes is an important part of assessment

• Medications — a significant number of adult cases are drug-induced (see the medications section below)

• HIV and antiretroviral therapy — certain antiretroviral agents, such as efavirenz, have been associated with gynaecomastia

It is also worth noting that gynaecomastia lasting longer than approximately 12 months is more likely to have undergone fibrotic change, which makes it less responsive to medical treatment — an important consideration when deciding on management.

Pseudogynaecomastia, by contrast, is primarily driven by excess body fat and is not associated with glandular tissue changes. It is more directly linked to being overweight or obese. Understanding which type is present is clinically important, as it guides the most appropriate management approach. A GP can help differentiate between the two through clinical examination and, where necessary, further investigations.

Further information is available on the NHS website: Gynaecomastia (enlarged male breasts).

When to See a GP About Gynaecomastia

See a GP promptly if you notice a hard or irregular lump, nipple discharge or retraction, skin changes, unilateral enlargement, or swollen axillary lymph nodes, as urgent 2-week wait referral may be required.

Many men feel embarrassed about enlarged breast tissue and may delay seeking medical advice. However, it is important to consult a GP if you notice any changes in your chest, as some causes of gynaecomastia require medical investigation and treatment. Early assessment can also provide reassurance and rule out more serious underlying conditions.

You should contact your GP promptly if you experience any of the following:

• Breast tissue that is tender, painful, or rapidly enlarging

• A hard or irregular lump beneath the nipple

• Nipple discharge (particularly if bloody or persistent) or nipple retraction

• Skin changes over the breast area

• Enlargement affecting only one side of the chest

• Swollen lymph nodes in the armpit

• Associated symptoms such as unexplained weight loss, fatigue, or testicular changes

• Breast changes that develop suddenly in adulthood without an obvious cause

Urgent referral: If your GP identifies suspicious features — such as a hard or irregular breast lump, unilateral nipple discharge or retraction, skin changes, or enlarged axillary lymph nodes — they should refer you urgently under the 2-week wait (suspected cancer) pathway, in line with NICE guideline NG12: Suspected cancer: recognition and referral. Primary care investigations should not delay this referral.

While gynaecomastia in adolescent boys during puberty is common and often resolves on its own within one to two years, it should still be assessed if it persists beyond this period or causes significant distress. In adult men, new-onset gynaecomastia warrants investigation to exclude secondary causes.

Your GP will typically take a thorough medical and medication history, perform a physical examination, and may arrange blood tests to assess hormone levels (including testosterone, oestradiol, LH, FSH, prolactin, and — where a testicular or other tumour is suspected — hCG), as well as liver and kidney function and thyroid function. Imaging such as mammography or testicular ultrasound is usually arranged by the specialist breast clinic following referral, rather than in primary care, to avoid any delay in assessment. Referral to an endocrinologist or breast surgeon may follow depending on findings.

The NHS provides clear pathways for investigating and managing gynaecomastia, and there is no need to manage this condition alone or without professional support.

Lifestyle Changes That Can Help Reduce Chest Fat

A calorie-controlled diet, regular cardiovascular and resistance exercise, and reducing alcohol can meaningfully reduce chest fat in pseudogynaecomastia, though lifestyle changes alone will not remove established glandular tissue.

For men whose chest enlargement is primarily due to pseudogynaecomastia (excess fatty tissue rather than glandular growth), targeted lifestyle modifications can be highly effective. Even in cases of true gynaecomastia, maintaining a healthy weight and active lifestyle supports overall hormonal balance and general wellbeing.

Weight management through diet is one of the most impactful steps. Since excess body fat promotes the conversion of androgens to oestrogens, reducing overall body fat can help restore a more favourable hormonal environment. A balanced, calorie-controlled diet rich in vegetables, lean proteins, whole grains, and healthy fats — and low in ultra-processed foods, refined sugars, and alcohol — is recommended. The NHS Eatwell Guide provides a practical framework for achieving this.

Regular physical activity is equally important. While it is not possible to target fat loss in a specific area of the body (so-called 'spot reduction' is not supported by evidence), a combination of:

• Cardiovascular exercise (e.g., brisk walking, cycling, swimming) to promote overall fat loss

• Resistance training (e.g., chest presses, push-ups, rows) to build pectoral muscle definition and improve chest appearance

...can make a meaningful difference over time, particularly for pseudogynaecomastia. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.

Alcohol reduction is also worth considering. Alcohol can suppress testosterone production and contribute to weight gain, both of which may worsen gynaecomastia.

Avoiding anabolic steroids, androgenic supplements, and prohormone products is strongly advised, as these can disrupt hormonal balance and contribute to gynaecomastia. Some herbal or phyto-oestrogenic products may also have hormonal effects; if you use any such supplements, discuss them with your GP or pharmacist.

Regarding recreational drugs such as cannabis, heroin, and amphetamines: these have been associated with gynaecomastia in some studies, though the evidence is largely observational and inconsistent. Nonetheless, avoiding illicit drug use is advisable for overall health.

It is important to understand that lifestyle changes alone are unlikely to resolve established glandular gynaecomastia — they improve general health and chest appearance but do not remove glandular tissue. They form an important foundation alongside any medical management.

Medical and Surgical Treatment Options

Tamoxifen (off-label, specialist-initiated) is the most commonly used medical treatment for early gynaecomastia; surgery — liposuction or glandular excision — is the most definitive option for established cases.

Where an underlying medical cause of gynaecomastia is identified — such as hypogonadism, hyperthyroidism, or a hormone-secreting tumour — treating the root cause is the primary approach and may lead to resolution of breast tissue changes over time. In cases where a causative medication has been identified, switching to an alternative under medical supervision may also result in improvement.

For persistent or symptomatic true gynaecomastia without a reversible cause, pharmacological treatment may be considered. It is important to note that no medications are currently licensed specifically for gynaecomastia in the UK, and any drug treatment is therefore used off-label, initiated by a specialist rather than in primary care.

• Tamoxifen (a selective oestrogen receptor modulator, SERM) is the most commonly used agent and may help reduce pain and tenderness, particularly in early or pubertal gynaecomastia. Evidence for significant reduction in glandular tissue is modest. As with all medicines, tamoxifen carries risks — including an increased risk of venous thromboembolism (VTE) — and individual contraindications must be assessed by the prescribing specialist. See the BNF monograph for tamoxifen and the emc SmPC for full prescribing information.

• Anastrozole (an aromatase inhibitor) is sometimes considered but evidence for its efficacy in gynaecomastia is limited, and it is not routinely recommended. See the BNF monograph for anastrozole for further detail.

Medical therapy is generally more effective when started within approximately 12 months of onset, before fibrotic changes develop in the glandular tissue. After this point, pharmacological treatment is less likely to produce meaningful regression.

Surgical treatment is the most definitive option for established gynaecomastia. The two main surgical approaches are:

• Liposuction — suitable for predominantly fatty tissue

• Mastectomy (glandular excision) — required when firm glandular tissue is present, sometimes combined with liposuction

NHS funding for gynaecomastia surgery is subject to criteria set by local NHS Integrated Care Boards (ICBs) and is informed by NHS England's Evidence-Based Interventions (EBI) programme, which classifies certain procedures as low clinical value unless specific clinical criteria are met. Access and eligibility therefore vary by region. Private surgical options are also widely available.

Referral to a breast surgeon or plastic surgeon is appropriate for men with persistent, symptomatic, or distressing gynaecomastia that has not responded to conservative management. Your GP can advise on local referral pathways and funding criteria.

Medications That May Contribute to Gynaecomastia

Spironolactone, finasteride, anti-androgens, digoxin, antipsychotics, and certain antiretrovirals are among the most commonly implicated drugs; never stop a prescribed medication without first consulting your GP.

A significant number of cases of gynaecomastia in adult men are drug-induced, and reviewing a patient's medication list is an essential part of clinical assessment. Various drug classes can disrupt the oestrogen-to-androgen ratio or directly stimulate breast tissue, leading to glandular proliferation. It is important to emphasise that patients should never stop a prescribed medication without first consulting their GP or specialist, as the risks of discontinuation may outweigh the benefits.

Commonly implicated medications include:

• Spironolactone — a diuretic with anti-androgenic properties, frequently used in heart failure and resistant hypertension; one of the most commonly implicated agents

• Finasteride and dutasteride — 5-alpha reductase inhibitors used for benign prostatic hyperplasia and male-pattern hair loss

• Anti-androgens (e.g., bicalutamide, cyproterone acetate) — used in prostate cancer management

• Digoxin — used in atrial fibrillation and heart failure; has weak oestrogenic activity

• Cimetidine — an older H2-receptor antagonist (now less commonly prescribed)

• Oestrogens and anabolic steroids/testosterone therapy — exogenous testosterone can be converted to oestradiol via aromatisation, paradoxically causing gynaecomastia

• Antiretrovirals — certain agents, including efavirenz, have been associated with gynaecomastia

• Ketoconazole and isoniazid — recognised as occasional contributors

• Antipsychotics (e.g., risperidone, phenothiazines) and dopamine antagonists (e.g., metoclopramide) — can elevate prolactin levels, which may contribute to breast tissue changes; some antidepressants may also raise prolactin, though this is less common

• Proton pump inhibitors (PPIs) — a weak association has been reported in some observational studies, but evidence is limited and a confirmed causal link has not been established

• Recreational drugs — cannabis, heroin, and amphetamines have been associated with gynaecomastia in some observational studies; evidence is inconsistent and should be interpreted with caution

For full prescribing information and adverse effect profiles, refer to the relevant BNF monographs and emc SmPCs.

If you believe a medication may be contributing to breast tissue changes, raise this with your GP, who can review whether an alternative treatment is appropriate. Both patients and healthcare professionals can report suspected adverse drug reactions — including gynaecomastia — via the MHRA Yellow Card scheme.

Frequently Asked Questions